Seven Fleet Capital Management LP Makes New Investment in Ascendis Pharma A/S $ASND

Seven Fleet Capital Management LP acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 5,670 shares of the biotechnology company’s stock, valued at approximately $1,209,000. Ascendis Pharma A/S comprises about 0.9% of Seven Fleet Capital Management LP’s holdings, making the stock its 17th biggest holding.

Several other large investors have also modified their holdings of the stock. Advisory Services Network LLC acquired a new stake in Ascendis Pharma A/S during the 3rd quarter worth $26,000. Arax Advisory Partners boosted its stake in Ascendis Pharma A/S by 212.2% in the fourth quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 104 shares in the last quarter. Leonteq Securities AG purchased a new position in shares of Ascendis Pharma A/S during the fourth quarter worth about $36,000. Jones Financial Companies Lllp grew its holdings in shares of Ascendis Pharma A/S by 57.2% during the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 83 shares during the last quarter. Finally, Global Retirement Partners LLC increased its position in shares of Ascendis Pharma A/S by 111.9% during the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 113 shares in the last quarter.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Jefferies Financial Group initiated coverage on Ascendis Pharma A/S in a report on Monday, March 16th. They issued a “buy” rating and a $290.00 target price for the company. Wolfe Research restated an “outperform” rating and set a $260.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Citigroup started coverage on Ascendis Pharma A/S in a research report on Monday, May 18th. They set a “buy” rating and a $355.00 price target on the stock. Wedbush reissued an “outperform” rating and issued a $273.00 price objective on shares of Ascendis Pharma A/S in a report on Thursday, April 9th. Finally, Wells Fargo & Company lowered their target price on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $295.39.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND opened at $230.83 on Friday. Ascendis Pharma A/S has a one year low of $160.86 and a one year high of $250.74. The stock has a market capitalization of $14.40 billion, a price-to-earnings ratio of 26.62 and a beta of 0.39. The company has a 50-day simple moving average of $232.36 and a 200-day simple moving average of $224.22. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.72 and a current ratio of 1.00.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11. The company had revenue of $285.45 million for the quarter, compared to analysts’ expectations of $362.47 million. On average, analysts predict that Ascendis Pharma A/S will post 4.92 EPS for the current year.

Insider Buying and Selling

In other news, insider Flemming Steen Jensen sold 19,460 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $238.49, for a total value of $4,641,015.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jean Jacques Bienaime purchased 400 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were bought at an average price of $237.80 per share, with a total value of $95,120.00. Following the purchase, the director directly owned 400 shares of the company’s stock, valued at approximately $95,120. The trade was a ? increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 40.00% of the stock is currently owned by company insiders.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark?based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long?acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once?weekly growth hormone therapy approved by the U.S.